SRR1337431
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.531
- PANCREAS_BETA_CELLS+0.333
- APICAL_SURFACE+0.303
- INFLAMMATORY_RESPONSE+0.264
- MYOGENESIS+0.240
- COAGULATION+0.222
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.217
- ALLOGRAFT_REJECTION+0.191
- KRAS_SIGNALING_UP+0.158
- ANGIOGENESIS+0.124
Top 10 suppressed
- MYC_TARGETS_V1-0.635
- OXIDATIVE_PHOSPHORYLATION-0.615
- PROTEIN_SECRETION-0.604
- UNFOLDED_PROTEIN_RESPONSE-0.549
- DNA_REPAIR-0.546
- MTORC1_SIGNALING-0.520
- MYC_TARGETS_V2-0.495
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.445
- ADIPOGENESIS-0.421
- E2F_TARGETS-0.411
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1448226 | GTEX | — | 0.972 |
| 2 | SRR1421093 | GTEX | — | 0.972 |
| 3 | SRR1468974 | GTEX | — | 0.969 |
| 4 | SRR1443979 | GTEX | — | 0.967 |
| 5 | SRR1485167 | GTEX | — | 0.967 |
| 6 | SRR1316624 | GTEX | — | 0.967 |
| 7 | SRR1440246 | GTEX | — | 0.967 |
| 8 | SRR1475803 | GTEX | — | 0.965 |
| 9 | SRR1474886 | GTEX | — | 0.962 |
| 10 | SRR1390582 | GTEX | — | 0.961 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.531 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.333 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.303 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.264 | Idelalisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.222 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.217 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.191 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.158 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.124 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.117 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.104 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.081 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.025 | Inavolisib | — uncovered |